Forte Biosciences Inc. Common Stock (FBRX)
FairStock Score: 10/100 — RISKY
Key Financials
| Current Price | $76.99 |
| Market Cap | $589M |
| P/E Ratio | -16.85 |
| ROE | -62.28% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Forte Biosciences is a clinical-stage biotech with a $589 million market cap at the 2026-08-28 close of $76.99. It has a lead molecule, FB102, aimed at celiac disease, vitiligo, and alopecia areata, but no approved products and no revenue growth figure is provided. As a Graham-style investor, I want durable earnings power and a margin of safety. Here, the FairStock-calculated P/E is -16.85, the P/B is 10.24, ROE is -62.28%, ROCE is -37.79%, and trailing free cash flow is -$72.0 million, a -12.2% FCF yield. That is a cash-consuming business with weak returns. The Piotroski F-Score of 1/9 and FairStock Score of 10/100 confirm poor fundamentals. The Altman Z-Score of 15.34 is one bright spot, suggesting low bankruptcy risk on that measure, but it does not create a moat. The computed Lynch category is none, because there are only 0 years of filed results and the rules need 3. The stock trades near its 52-week high of $77.20, far above its $10.30 low, with a beta of 2.65. That is speculative territory. A biotech moat, if any, comes from patents and trial data, not current financials. Without revenue growth or profits, the story depends entirely on FB102's clinical success. At this price, I see no margin of safety.
In plain English: Forte Biosciences is a small testing-stage drug company working on treatments for autoimmune diseases. It has no approved medicine yet, is losing money, and spends more cash than it brings in. The stock is near its 52-week high, so the price looks expensive compared with today's weak financial results.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-08-28 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer